{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Double-Blind+Adalimumab%2FPlacebo+%2B+MTX", "query": { "intervention": "Double-Blind Adalimumab/Placebo + MTX" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Double-Blind+Adalimumab%2FPlacebo+%2B+MTX&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T23:24:57.674Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00298272", "title": "Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "IDEC-C2B8 (rituximab)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Folate", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 54, "start_date": "2006-05", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2015-09-28", "last_synced_at": "2026-10-07T23:24:57.674Z", "location_count": 18, "location_summary": "Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00298272" }, { "nct_id": "NCT02889796", "title": "Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Filgotinib", "type": "DRUG" }, { "name": "Placebo to match filgotinib", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo to match adalimumab", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1759, "start_date": "2016-08-30", "completion_date": "2019-06-20", "has_results": true, "last_update_posted_date": "2021-06-09", "last_synced_at": "2026-10-07T23:24:57.674Z", "location_count": 48, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Hemet", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02889796" }, { "nct_id": "NCT02629159", "title": "A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo for Adalimumab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo for Upadacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1629, "start_date": "2015-12-01", "completion_date": "2027-09-30", "has_results": true, "last_update_posted_date": "2025-08-05", "last_synced_at": "2026-10-07T23:24:57.674Z", "location_count": 109, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02629159" }, { "nct_id": "NCT02833350", "title": "Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "GDC-0853", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 578, "start_date": "2016-09-09", "completion_date": "2018-07-02", "has_results": true, "last_update_posted_date": "2020-06-12", "last_synced_at": "2026-10-07T23:24:57.674Z", "location_count": 23, "location_summary": "Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "El Cajon", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02833350" }, { "nct_id": "NCT00195663", "title": "Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Rheumatoid Arthritis" ], "interventions": [ { "name": "Adalimumab", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Adalimumab placebo", "type": "BIOLOGICAL" }, { "name": "Methotrexate placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 799, "start_date": "2000-12", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-07-12", "last_synced_at": "2026-10-07T23:24:57.674Z", "location_count": 31, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 24 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00195663" }, { "nct_id": "NCT00235820", "title": "Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "adalimumab", "type": "DRUG" }, { "name": "MTX", "type": "DRUG" }, { "name": "placebo adalimumab, placebo MTX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 271, "start_date": "2005-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-07-17", "last_synced_at": "2026-10-07T23:24:57.674Z", "location_count": 1, "location_summary": "Abbott Park, Illinois", "locations": [ { "city": "Abbott Park", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00235820" }, { "nct_id": "NCT01004432", "title": "Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis", "Arthritis, Rheumatoid", "Autoimmune Diseases" ], "interventions": [ { "name": "Golimumab 50 mg SC", "type": "DRUG" }, { "name": "Golimumab 2 mg/kg IV", "type": "DRUG" }, { "name": "Methotrexate (MTX)", "type": "DRUG" }, { "name": "Placebo SC", "type": "DRUG" }, { "name": "Placebo IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 433, "start_date": "2009-12", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-10-07T23:24:57.674Z", "location_count": 89, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01004432" }, { "nct_id": "NCT00048542", "title": "Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Juvenile Idiopathic" ], "interventions": [ { "name": "Double-Blind Adalimumab/Placebo + MTX", "type": "BIOLOGICAL" }, { "name": "Double-Blind Adalimumab/Placebo", "type": "BIOLOGICAL" }, { "name": "OLE BSA Adalimumab +/- MTX", "type": "DRUG" }, { "name": "OLE FD Adalimumab +/- MTX", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Years to 17 Years" }, "enrollment_count": 171, "start_date": "2002-09", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2011-08-22", "last_synced_at": "2026-10-07T23:24:57.674Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048542" }, { "nct_id": "NCT01710358", "title": "A Study in Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Adalimumab Placebo", "type": "DRUG" }, { "name": "Baricitinib Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1307, "start_date": "2012-10", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-10-07T23:24:57.674Z", "location_count": 45, "location_summary": "Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 39 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01710358" }, { "nct_id": "NCT00420927", "title": "Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "adalimumab", "type": "BIOLOGICAL" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1032, "start_date": "2006-12", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2012-04-18", "last_synced_at": "2026-10-07T23:24:57.674Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00420927" } ] }